Related Experiment Video
Updated: Mar 13, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.6K
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas1, Marta Ruiz-Lopez1, Susan H Fox2
1Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada.
CNS Drugs
|October 16, 2016
Summary
New levodopa formulations aim to improve Parkinson's disease treatment by enhancing bioavailability through innovative oral and alternative delivery methods, addressing declining therapeutic responses.
Area of Science:
- Neurology
- Pharmacology
- Gastroenterology
Background:
- Levodopa is the gold standard for Parkinson's disease (PD) treatment.
- Disease progression and GI changes limit levodopa's therapeutic window.
- Novel formulations seek to overcome these limitations and improve patient outcomes.
Purpose of the Study:
- To review novel levodopa formulations for Parkinson's disease.
- To summarize pharmacokinetic profiles, clinical efficacy, and adverse events.
- To provide an overview of available and investigational levodopa therapies.
Main Methods:
- Review of recent scientific literature on levodopa formulations.
- Analysis of pharmacokinetic data and clinical trial results.
- Comparison of different routes of administration and formulation types.
Main Results:
- Several novel formulations are approved or in development, including extended-release oral options (IPX066, AP09004), intestinal infusion (LCIG), subcutaneous delivery (ND0612), and inhaled powders (CVT-301).
- Some formulations have been discontinued (DM-1992, XP21279).
- New combinations like ODM-101 are also being explored.
Conclusions:
- Innovative levodopa formulations offer promising strategies to manage Parkinson's disease by improving drug delivery and sustained therapeutic effects.
- These advancements aim to extend the window of response and enhance quality of life for PD patients.
- Ongoing research is crucial for optimizing levodopa therapy through novel drug delivery systems.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K